UNSPSC 51131711: Tenecteplase

This classification denotes a thrombolytic agent with the molecular formula C2558H3872N738O781S40, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WGD229O42W, more generally known as tenecteplase. European Medicines Agency schedules tenecteplase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04718MIG. The term TENECTEPLASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 13 no. 1, 1999, list 41.

Most nations schedule tenecteplase under HS 35079090 and SITC 51691. As of Q4 2014, TENECTEPLASE remains the US FDA Preferred Term for this commodity. Tenecteplase bears US NLM identifiers UMLS ID C0872913 and NCI Concept Code C29489. SMILES: NONE.

UNSPSC 51131711 Tenecteplase is a Commodity code that represents a specific pharmaceutical product — a tissue plasminogen activator used in emergency medical treatment — yet the recent state and local procurement activity tagged to this code shows no alignment with pharmaceutical procurement. The single recent opportunity on record is Sourcewell RFP #061626, posted May 12, 2026 with a June 16, 2026 response deadline, which solicits law enforcement equipment through a cooperative purchasing vehicle. This disconnect suggests the code has been misapplied to the opportunity or that the source data does not capture authentic pharmaceutical procurement under 51131711. The solicitation itself is a multistate cooperative RFP issued by Sourcewell, a Minnesota local government unit, on behalf of participating entities including Franklin, Grant, Grays Harbor, Chelan, and Yakima Counties in Washington and numerous other jurisdictions across the United States and Canada, aimed at establishing a framework agreement available to governmental agencies, school districts, higher education institutions, nonprofits, and tribal governments.

No recent opportunities in the source data reflect actual procurement of tenecteplase or pharmaceutical products aligned with the Commodity code's nominal scope. The geographic spread and issuing-body mix cannot be reliably characterized from a single misaligned opportunity. If tenecteplase procurement under this code is occurring at the state and local level, it is not reflected in the available recent solicitation records. Business development professionals should verify whether this code is actively used by state and local health departments, hospital systems, or emergency medical service authorities before investing significant pursuit effort; the current signal is too weak to support targeting.